Swiss Startup Arcoris Bio Secures $7.1M to Revolutionize Biomarker Detection with Nanotech Platform

Schlieren, Switzerland – November 7, 2025 – Arcoris Bio, a Swiss life science tools and in vitro diagnostics company, has closed a CHF 6.3 million (approximately $7.1 million USD) seed funding round led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and private investors. The financing will accelerate the industrialization and commercialization of the company’s breakthrough MUSE® biomarker detection platform, aiming to transform the field of digital pathology.

This investment signals strong confidence in Arcoris Bio’s technology and business strategy, particularly within a rapidly expanding digital pathology market. Industry analysts predict the global market will reach $8.8 billion in 2023 and expand at a CAGR of 12.1% through 2030, driven by advancements in biomarker detection technologies.

MUSE®: Amplifying Signals for Enhanced Diagnostics

The core of Arcoris Bio’s innovation lies in its MUSE® (Multiplexed Universal Signal Enhancement) platform. This nanotechnology-based system dramatically amplifies biomarker signals, allowing for the detection of even low-abundance biomarkers with unprecedented sensitivity and the simultaneous analysis of multiple biomarkers – a capability known as multiplexing. This is a crucial step forward, as traditional methods often struggle with sensitivity and the ability to assess multiple factors simultaneously.

“The challenge in biomarker detection is often finding the ‘needle in the haystack’ – identifying those crucial signals amidst a lot of noise,” explains a source close to the company. “MUSE® acts as a sophisticated amplifier, making those faint signals much easier to detect and analyze.”

The platform’s potential extends across a wide range of applications, including cancer diagnostics, infectious disease detection, and personalized medicine. By enabling faster and more accurate diagnoses, MUSE® promises to improve patient outcomes and reduce healthcare costs.

A Strategic Investment in a Growing Market

The CHF 6.3 million seed round will be instrumental in scaling up production and forging strategic partnerships to bring MUSE® to market. According to the company, funds will be allocated to optimizing the manufacturing process, expanding the team, and initiating clinical validation studies.

Ventura Ace and ZEISS Ventures, both prominent investors in the life science sector, were drawn to Arcoris Bio’s innovative technology and the potential for significant impact. “We are impressed by the team’s scientific expertise and their commitment to developing a truly disruptive technology,” says a partner at Ventura Ace. “MUSE® has the potential to revolutionize biomarker detection and become a cornerstone of future diagnostic workflows.”

ZEISS Ventures, with its focus on optics and life sciences, sees a strong synergy between Arcoris Bio’s platform and its own portfolio of technologies. “The ability to amplify signals and analyze multiple biomarkers simultaneously is critical for advancing precision medicine,” explains a representative from ZEISS Ventures. “We believe MUSE® will play a key role in enabling more personalized and effective treatments.”

The Competitive Landscape and Arcoris Bio’s Differentiation

The digital pathology market is becoming increasingly competitive, with established players like Roche Diagnostics, Philips Healthcare, and Illumina vying for market share. However, Arcoris Bio’s nanotechnology-based approach offers a unique advantage. While many existing platforms rely on traditional detection methods, MUSE®’s signal amplification technology provides a significant boost in sensitivity and multiplexing capabilities.

“Current diagnostic methods often struggle with detecting biomarkers present in low concentrations,” notes an industry analyst. “MUSE® addresses this challenge head-on, allowing for earlier and more accurate diagnoses.”

Furthermore, the company’s focus on multiplexing enables the simultaneous analysis of multiple biomarkers, providing a more comprehensive understanding of a patient’s condition. This capability is particularly valuable in complex diseases like cancer, where multiple factors contribute to disease progression.

Building a Team and Validating the Technology

Arcoris Bio was founded by a team of experienced scientists and entrepreneurs with a deep understanding of nanotechnology, biomarker detection, and diagnostic development. Simon Restrepo, co-founder and CEO, brings extensive experience in biochemistry and nanotechnology. Scott E. Fraser, co-founder and Chief Scientific Officer, is a renowned expert in digital pathology and biomedical imaging, and H. Kaspar Binz, CTO, boasts expertise in materials science and medical device development.

The company is currently focused on completing clinical validation studies to demonstrate the accuracy and reliability of the MUSE® platform. These studies will be crucial for obtaining regulatory approvals and gaining acceptance from healthcare providers.

“The next step is to translate the promising results we’ve seen in the lab into real-world clinical applications,” says a source familiar with the company’s plans. “We are confident that MUSE® will become an indispensable tool for pathologists and clinicians worldwide.”

The successful completion of this seed funding round marks a significant milestone for Arcoris Bio, positioning the company for continued growth and innovation in the rapidly evolving field of digital pathology. With a strong team, a disruptive technology, and the backing of leading investors, Arcoris Bio is poised to make a lasting impact on the future of diagnostics and personalized medicine.